A Randomized, Double-blinded, Clinical, Placebo-controlled Trial on the Effects of Therapy With Letrozole and hUman Choriongonadotropin in Male Hypogonadism Induced by Illicit Use of Anabolic Androgenic Steroids- The LUCAS Trial

Hypogonadism Clinical Trial

Official title:

A Randomized, Double-blinded, Clinical, Placebo-controlled Trial on the Effects of Therapy With Letrozole and hUman Choriongonadotropin in Male Hypogonadism Induced by Illicit Use of Anabolic Androgenic Steroids on Plasma Reproductive Hormones, Fertility, Withdrawal Symptoms and Myocardial Function - The LUCAS Trial

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT05205837
• Other study ID #: H-20036287
• Secondary ID: 2020-002612-52
• Status: Terminated
• Phase: Phase 4
• Start date: November 24, 2021
• Est. completion date: August 15, 2023

Study information

• Verified date: February 2024
• Source: Rigshospitalet, Denmark
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The overall objective of this randomized trial is to investigate the effects of treatment of AAS- induced male hypogonadism with combined therapy of letrozole and hCG compared with placebo on reproductive hormone levels, adherence to cessation of AAS use, fertility, cardiac function and quality of life.

Description:

A randomized, double-blinded, clinical, placebo-controlled trial enrolling 60 male illicit AAS users with documented AAS-induced hypogonadism after a period > 12 weeks of AAS cessation or a negative urine AAS doping test. Participants will be randomized to two study groups; 24 weeks of treatment with either tablet letrozole (femar®) initial dose of 2.5 mg each day versus tablet placebo. After an initial treatment period of four weeks, intramuscular injections with either hCG, initial dose 1500 IE twice weekly (letrozole group) or isotonic saline twice weekly (placebo group) will be added to therapy if plasma total testosterone level has not increased to target plasma level. Following 24 weeks of therapy, all participants will be observed for another 26 weeks without therapy. The study will have one trial center of recruitment: Department of Endocrinology, Rigshospitalet. Following participation in the study, all participants will be offered referral to an endocrine outpatient clinic if they still display clinical and biochemical signs of male hypogonadism. A healthy group of 30 young lean eugonadal men, who have never used AAS, will be enrolled as control participants and undergo a screening visit and one visit including same procedures as the screening and randomization visits.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 8
• Est. completion date: August 15, 2023
• Est. primary completion date: August 15, 2023
• Accepts healthy volunteers: No
• Gender: Male
• Age group: 18 Years to 50 Years

Eligibility

Inclusion Criteria:

• • Male sex
• 18 - 50 years of age
• Hypogonadism following observational period of a minimum of 12 weeks since AAS discontinuation OR hypogonadism with a urine sample negative for AAS analyses at screening visit: plasma total testosterone = 10 nmol/L AND featuring at least one symptom of male hypogonadism using IIEF in terms of erectile function (IIEF: Q1 - Q5 + Q15; total score < 26) and/or sexual desire (IIEF: Q11 + Q12; total < 7) (1) and/or ADAM questionnaire (YES to three questions other than question 1 and 7) and/or regular use of medical treatment for erectile dysfunction.
• Motivation for permanent AAS cessation

Exclusion Criteria:

• Established cardiovascular disease
• Established diabetes of any kind 384
• Congenital hypogonadal conditions (cryptorchidism, Klinefelter's disease, Kallmann's disease etc.)
• Previous established hypogonadal conditions due to other causes than illicit use of AAS
• Current or previous treatment with testosterone on other indication than AAS-induced male hypogonadism
• Abnormal puberty development (small testes, late or absent pubic hairing, late or absent deepening of voice, etc.)
• Current or previous pituitary diseases including pituitary tumors
• Current or previous tumors of the hypothalamus
• Current or former testicular cancer
• Current or previous prostate cancer
• Current or previous breast cancer
• Other cancers unless complete remission = 5 year
• Other concomitant disease or makes the patient unsuitable to participate in the study
• Severely impaired liver function
• Allergy or hypersensitivity to the active substance (letrozole) or excipients of Letrozol "Accord"® listed in Appendix D
• Allergy or hypersensitivity to the active substance (hCG) or excipients of Brevactid® listed in Appendix D
• Established Lapp lactase deficiency or glucose/galactose malabsorption
• Severe venous phlebitis or current or previous venous thromboembolism
• Inguinal hernia
• treatment which according to the investigators' assessment
• Simultaneous participation in another clinical study
• Unable to follow treatment instructions in terms of study medication instructions
• Ongoing criminal behavior in terms of violence or illicit distribution of drugs
• Currently or in the foreseeable future included in anti-doping programs

Related Conditions & MeSH terms

• Hypogonadism
• Hypogonadism, Male
• Hypogonadotropic Hypogonadism

Intervention

Drug:
• Letrozole 2.5mg, hCG
Drug -Treatment Intramuscular injektion - Treatment
• Placebo
Drug - Placebo Intramuscular injektion - placebo

Locations

Country	Name	City	State
Denmark	Rigshospitalet	Copenhagen

Sponsors (1)

Lead Sponsor	Collaborator
Rigshospitalet, Denmark

Country where clinical trial is conducted

Denmark, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in plasma total testosterone concentration after 24 weeks from baseline		24 weeks
Secondary	Number of participants who adhere to AAS cessation after 24 and 50 weeks from baseline		24 and 50 weeks
Secondary	Change in total plasma testosterone concentration after 50 weeks from baseline		50 weeks
Secondary	Change in plasma total testosterone secretion in response to hCG stimulation after 24 and 50 weeks from baseline		24 and 50 weeks
Secondary	Change in basal plasma pituitary gonadotropins, LH and FSH, after 24 and 50 weeks from baseline		24 and 50 weeks
Secondary	Change in secretion of plasma pituitary gonadotropins, LH and FSH, in response to GnRH stimulation after 24 and 50 weeks from baseline		24 and 50 weeks
Secondary	Change in sperm count after 24 and 50 weeks from baseline		24 and 50 weeks
Secondary	Change in sperm motility after 24 and 50 weeks from baseline		24 and 50 weeks
Secondary	Change in sperm morphology after 24 and 50 weeks from baseline		24 and 50 weeks
Secondary	Change in sperm acrosome reaction after 24 and 50 weeks from baseline		24 and 50 weeks
Secondary	Change in sperm DNA fragmenting after 24 and 50 weeks from baseline		24 and 50 weeks
Secondary	Change in testicular size assessed using ultrasound after 24 and 50 weeks		24 and 50 weeks
Secondary	Change in questionnaire score IIEF (erectile function and libido) from baseline and after 24 and 50 weeks		24 and 50 weeks
Secondary	Change in questionnaire score ADAM (hypogonadism) from baseline and after 24 and 50 weeks		24 and 50 weeks
Secondary	Change in questionnaire score of Major Depression Inventory (MDI) (depression) from baseline and after 24 and 50 weeks		24 and 50 weeks
Secondary	Change in questionnaire score of (GAD7) (anxiety) from baseline and after 24 and 50 weeks		24 and 50 weeks
Secondary	Change in questionnaire score of Buss-Perry Aggression scale (BPA) (hostility and aggression) from baseline and after 24 and 50 weeks		24 and 50 weeks
Secondary	Change in questionnaire score of COBRA (Cognitive complaints in bipolar disorder rating assessment) from baseline and after 24 and 50 weeks		24 and 50 weeks
Secondary	Change in questionnaire score of the Health Assessment Short Form-36 questionnaire from baseline and after 24 and 50 weeks		24 and 50 weeks
Secondary	Change in questionnaire score of Body-Q 349 (Perception of own body) from baseline and after 24 and 50 weeks		24 and 50 weeks
Secondary	Change in questionnaire score of the Inventory of Interpersonal Problems 32-item (IIP32) from baseline and after 24 and 50 weeks		24 and 50 weeks
Secondary	Change in myocardial function assessed by myocardial flow reserve (mL/min/gr) by Rb-82 PET from baseline and after 24 and 50 weeks		24 and 50 weeks
Secondary	Change in cardiac systolic function assessed using left ventricular ejection fraction (LVEF) obtained using echocardiography and 24 and 50 weeks from baseline.		24 and 50 weeks
Secondary	Change in cardiac systolic function assessed using left ventricular global longitudinal strain (GLS) obtained using echocardiography and 24 and 50 weeks from baseline.		24 and 50 weeks
Secondary	Change in cardiac structure (left ventricular mass) obtained using echocardiography and 24 and 50 weeks from baseline.		24 and 50 weeks